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1. Introduction  
When instability of the lumbar spine causes persistent pain or neurological impairment, it is 
usually treated by spinal fusion. Unfortunately, despite the development of spinal 
instrumentation such as pedicle screws, rods and intervertebral cages, nonunion rates are 
still close to 15%. Autogenous bone grafting has been the gold standard as the bone graft 
material of choice, however, its use has several disadvantages, such as a limited supply and 
a reasonable percentage of donor site problems. For these reasons, alternative sources of 
bone grafting materials or replacements have been explored and developed. One possibility 
is the use of bone morphogenetic proteins (BMPs), which belong to the transforming growth 
factor (TGF) superfamily and are known to be capable to eliciting new bone formation can 
provide an alternative to bone grafting (Reddi et al., 1998, Khan et al., 2002, Vaccaro et al., 
2002, Veillette et al., 2007). Three types of BMP- based bone tissue engineering have been 
tried to date: cell therapy involving the transplantation of autogenous mesenchymal cells 
differentiated by BMP, gene therapy involving the transduction of genes encoding BMPs 
into cells at the repair site (Kaito et al, 2005), and cytokine therapy involving recombinant 
BMP and carriers that retain and release BMP as needed. Of the three types of BMP-based 
bone tissue engineering techniques, cytokine therapy has received significant attention. 
Several kinds of combination with cytokine and carriers were reported (Khan et al., 2004). 
However, uncontrolled release of high dose BMP has been known to cause inflammation, 
soft tissue edema, and unintended bone formation (Carlisle et al., 2005, Mroz et al., 2010). 
An alternative to recombinant proteins, is the use of novel methods and gene transfer 
techniques to achieve bone formation in the spine. Gene therapy is ideal for orthopaedic use 
because, in most cases, local and transient expression of osteogenic factors is necessary for 
bone formation (Helm et al., 2000). Regional gene therapy for spinal fusion is an attractive 
option to treat multi-operated unstable spines where osteogenic cells, blood supply and 
bone stock are limited (Wang et al., 2003). 
The recent progress in molecular biology, genetics, and stem cell biology demonstrate that 
gene therapy for spinal fusion could result in effective bone formation by sustained and 
controlled release of osteogenic factors (Yoon et al., 2004). Ex vivo gene therapy, which is the 
combination of gene therapy and cell therapy, is currently the most fascinating areas of 
orthopedic research and surgery. In this chapter, the authors summarize the latest research 
in ex vivo gene therapy for spinal fusion and discuss the clinical implications of these 
treatments. 
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2. Ex vivo gene therapy  
Regional gene therapy is ideal for spinal fusion because local and transient expression of 
osteogenic factors is necessary for bone formation, compared to systemic genetic disorders 
in which consistent and systemic expression of specific genes are required (Baltzer et al., 
2004). Therefore, there is more flexibility with respect to the use of vectors for treatment of 
these problems and it may stave off the side effects associated with the current use of high 
dose and uncontrolled release of recombinant BMPs (Mroz et al., 2010). Regional gene 
therapy can be employed via either an in vivo or an ex vivo approach. In an in vivo technique, 
the vector is delivered directly to the target site. The advantage of the in vivo approach is 
that it involves only one step. The disadvantages of this technique are that it is more difficult 
to transduce cells in vivo, and one cannot select the target cells that will be transduced. 
Reports of successful fusion using the in vivo approach have been mostly reported in 
athymic rats (Alden TD et al., 1999). On the other hand, in an ex vivo approach, the vector is 
delivered into harvested cells. The transduced cells are then implanted into a specific 
regeneration site. The advantage of the ex vivo technique is that there is an increased 
transduction efficiency and safety as compared to when performed in vitro. In addition, the 
transduced mesenchymal stem cells (MSCs) could act not only as a production plant for 
osteogenic factors, but also as a source of osteogenic cells. The ex vivo technique also allows 
for attachment of a desirable carrier material which can act as an osteoconductive scaffold 
(Oakes DA et al., 2000). The disadvantage of this strategy is that this approach is more labor 
intensive, and therefore may not be cost-effective (Phillips et al., 2005). 
3. Vectors for gene delivery 
3.1 Non-viral vectors  
Vectors may be classified broadly as either viral (Kootstra et al., 2003) or non-viral (Li S et 
al., 2001). Non-viral vectors are easy to handle, chemically more stable than viruses and 
have no limit as to the size of the genetic materials that can be introduced into the cell. 
However their use is limited because the transfection efficiency is low and the duration of 
expression of the protein product tends to be short due partly to the episomal nature of the 
transgene. Non-viral gene delivery includes direct injection of naked DNA, direct injection 
or liposomal transfection of plasmids and particle-mediated gene transfer (i.e.; gene gun). 
Plasmids are circular DNA initially found in bacteria and work to acquire resistance to 
antibiotics. They are usually used in combination with cationic liposomes or scaffolds to 
form what has been termed the “gene activated matrix” (GAM) (Fang et al., 1996). A 
particle-mediated transfer (gene gun) is a projection of a metallic particle coated with DNA 
by electrical charge or gas pressure into the target cells. The disadvantage of this technique 
is transient and limited gene expression and toxicity caused by metal particles (Benn et al., 
1996).  Despite many advantages such as the ability to transfer a large amount of DNA, a 
decreased risk of insertion into the host DNA and no incitement of immune response (repeat 
administration is possible), the low gene transduction rate and short-time gene expression 
are limiting the use of these non-viral vectors. Current investigations are attempting to 
overcome these limitations. 
3.2 Viral vectors 
Currently, the most efficient vectors are utilize viruses. Viral vectors are usually designed so 
that genes required for viral replication are replaced by a specific therapeutic gene of 
interest. The resulting recombinant vector is replication incompetent. However, they are still 
www.intechopen.com
 Ex Vivo Gene Therapy for Spinal Fusion 
 
229 
able to deliver genetic material directly to a cell’s nucleus efficiently, and then the cellular 
machinery can produce the therapeutic protein coded by the introduced genetic material. 
Vectors vary in the efficiency of gene transfer, the genetic carrying capacity, ease of 
production, and reactions with host immunity (Khan et al., 2000, Alden et al., 2002, Evans et 
al., 2004, Nishida et al., 2008).  
3.2.1 Retrovirus 
Retroviral vectors have single-stranded RNA and have been derived from oncoretroviruses 
such as the murine leukemia virus (MLV). The advantage of using a retroviral vector is that 
it transduces the genes into the host chromosomes very efficiently and reliably during cell 
division (Miller DG et al., 1990). Therefore the integrated genes are passed on to subsequent 
daughter cells, giving the gene the potential for lifelong expression. However, this 
integration may occur only during cell division, thus, only highly proliferative cells can be 
transduced with retroviral vectors. Therefore, it may not be suitable for in vivo direct 
injection. Some of the major disadvantages of retroviral vectors are the low infectivity, 
instability of their virions, a limited capacity of genetic materials (~8kb) and risk of 
oncogenesis by the insertion of genetic materials (Li et al., 2002). There have also been 
concerns about the potential ability of the recombinant retroviruses to convert into 
replication competent viruses.  
3.2.2 Adenovirus 
The most commonly tested viral delivery vehicle for gene therapy for bone healing has been 
the adenovirus. Adenoviruses are double-stranded DNA viruses with a genome size of 
approximately 35kilobases. The genetic material is inserted into the nucleus in an episomal 
state, and not integrated within the host chromosome. The viral genome is divided into 
immediate early genes, early genes, and late genes according to the time during which the 
genes are expressed. First-generation adenoviral vectors often have deleted the E1and E3 
region which necessary for virus replication and can accommodate up to 8kb of foreign 
DNA (Lai et al., 2002). Recombinant adenoviral vectors can be produced at high levels, 
transfer genes to both dividing cells and non-dividing cells efficiently, and maintain more 
genetic material than other viruses (Gugala et al., 2003). The transgene remains episomal so 
that the therapeutic gene expression is stopped when the genetically modified cell divides. 
This episomal nature reduces the risk of insertional mutagenesis. The main disadvantage of 
the adenovirus is the high immunogenic potential. The humoral and cellular immune 
responses can actually remove the transduced cells, resulting in decreased gene expression 
(McCoy et al., 1995). Also, the immunologic memory established against the viral vector by 
the initial exposure limits the ability to give a second administration of gene therapy. Newer 
formulations of adenovirus vectors have undergone removal of many viral antigens to 
minimize this challenge and the so-called gutless vectors have virtually no adenovirus genes 
to minimize these responses (Hammerschmidt et al., 1999). As another approach for this 
immunological response, transient immunosuppression using cyclophosphamide has been 
shown to improve BMP expression after BMP adenoviral vector gene therapy (Okubo et al., 
2000, Kim et al., 2003). Lieberman et al used ex vivo adenoviral gene transfer to create BMP-2 
producing bone marrow cells for the delivery of BMP-2 to heal a critical-sized femoral 
segmental defect in a rat model (Lieberman et al., 1998). The genetically modified cells were 
implanted with inactivated demineralized bone matrix as a substrate. At two months, 92% 
of the defects healed radigraphically, and there was no significant difference in 
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biomechanical testing between the group that had been treated with genetically modified 
cells and those that had been treated with rhBMP-2 alone. Their results showed that BMP-2 
producing bone marrow cells created by means of adenoviral gene transfer produced 
sufficient proteins to heal a segmental femoral defect in a rat model.  
3.2.3 Adeno associated virus 
Adeno-associated viruses (AAVs) are a defective single stranded parvovirus (requires a 
helper virus such as adenovirus or herpes simplex virus for replication) that integrates its 
genetic material into a specific site located on chromosome 19 which can minimize the risk 
of insertional mutagenesis (Monahan et al., 2000). The virus infects a wide variety of 
dividing and non-dividing cells with high efficiency and little inflammatory response. Also, 
long-term gene expression has been reported in several tissues types. The disadvantages of 
AAVs are the difficulty in the virus production and limited titers of virus which can be 
generated (Kotin et al., 1994).  
3.2.4 Herpes virus 
Herpes viruses are double-stranded DNA viruses that can cause significant human 
pathology, including cold sores and encephalitis. Gene therapy studies using herpes viral 
vectors typically use genetically modified herpes simplex Type 1 (HSV-1). Herpes viral 
vectors have the advantage of being able to accommodate up to 40 kb of foreign DNA, and 
can be used to a variety of cell populations with limited toxicity (Evans et al., 1997). 
However, the disadvantage is that HSVs are highly immunogenic. 
3.2.5 Lentivirus 
Whereas retroviruses can only infect dividing cells, lentiviruses such as the human 
immunodeficiency virus type 1 (HIV-1) can also infect non-proliferating cells. What could be 
termed the third-generation lentivirus conserves only three (gag, pol, and rev) of the nine 
genes present in the genome of the original HIV-1. This eliminates the possibility that a wild 
-type virus will be reconstituted through recombination and create room for a relatively 
large gene delivery. Lentiviral-based gene transfer provides improved delivery, integration, 
and expression of target genes in vitro as well as in vivo. Furthermore, lentiviruses are 
capable of inserting into the host genome ensuring prolonged gene expression with a 
limited host immune response (Feeley et al., 2006). However, safety issues of HIV-based 
vectors are a major concern when adapting these vectors for clinical use (Bai et al., 2003, Dull 
et al., 1998, Zufferey et al., 1997, Zufferey et al., 1998).  
4. Osteoinductive factors for ex vivo gene therapy 
4.1 BMPs 
BMPs comprise a large and diverse family, and many may have a distinct role not only in 
the cascade of bone morphogenesis but also in orchestrating tissue architecture throughout 
the body. More than 20 BMPs have been identified in humans and rodents (Bragdon B et al., 
2011). Signal transduction of BMPs consists of interaction with both type-1(BMPR-1) and 
type-2(BMPR-2) BMP receptors, phospholylation of the GS domain of BMPR-1 by BMPR-2, 
phosphorylation of Smad1/5/8, and the translocation of the Smad1/5/8 partnering with the 
Smsd4 to the nucleus to activate the transcription for BMP-response genes (Reddi et al., 
2001, Bragdon B et al., 2011). To date, most attempts at gene therapy to achieve spinal fusion 
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have involved transfection with various BMPs (Li et al., 2003). Among BMPs, BMP-2 and 
BMP-7 have been the most extensively studied, both in animal studies and in clinical trials 
of spinal fusion. Recently, some combinations of BMPs have been demonstrated to have a 
synergic effect on bone formation (Israel et al., 1996, Zhu et al., 2004, Zhao et al., 2005). 
4.2 LIM 
LIM mineralization protein-1 (LMP-1) is an intracellular LIM-domain protein that is directly 
involved in osteoblast differentiation. LMP-1 also appears to elicit the increased synthesis of 
BMPs. Unlike a BMP, which is a secreted protein that binds to cell-surface receptors to 
initiate a response, LMP-1 is an intracellular signaling molecule and must be synthesized 
inside cells to exert its osteoinductive effects. Thus, the use of LMP-1 to form bone must 
involve the techniques of gene therapy to deliver the cDNA inside the cells and result in the 
synthesis of LMP-1 protein in situ (Cha et al., 2003, Pola et al., 2004). 
4.3 NELL-1 
NELL-1 (NEL-like molecule-1; NEL[a protein strongly expressed in neural tissue encoding 
epidermal growth factor like domain]) is a novel growth factor believed to specifically target 
cells committed to the osteochondral lineage. NELL-1 was isolated and characterized in 
craniosynostosisi patients as specifically upregulated within prematurely fusing sutures 
(Zhang et al., 2002). The phenotype of the Nell-1 transgenic overexpression mouse revealed 
cranial suture overgrowth similar to human craniosynostosis, suggesting a distinct role for 
Nrll-1 in bone formation. Conversely, a mouse model with mutated RNU-induced alleles, 
including Nell-1, resulted in cranial and other vertebral skeletal defects (Desai et al., 2006). 
In committed osteoblasts, Nell-1 upregulation accelerates osteogenic differentiation and 
bone formation. Interestingly, human NELL-1 was reported to be directly regulated by 
Cbfa1/Runx2, confirming its osteochondral specificity (Truong S et al., 2007). Additionally, 
co-administration to C2C12 myoblasts with AdBMP-2 and AdNell-1 showed a synergistic 
effect on osteogenic differentiation as detected by alkaline phosphatase activity and 
osteopontin production. Importantly, Nell-1 alone did not induce osteogenic differentiation 
of myoblasts. 
5. Cells combined with ex vivo gene therapy 
MSCs from adult tissues present fewer ethical and tumorigenicity problems in their use than 
embryonic stem (ES) cells. These MSCs have demonstrated not only self-renewal ability but 
also “plasticity” meaning they have the ability to differentiate into phenotypes not restricted 
to the tissue from which they are derived (Augello et al., 2010). Another key feature of these 
MSCs is their rapid expansion in vitro without loss of progenitor characteristics. Various 
sources of MSCs that could be used for ex vivo gene therapy include bone marrow, muscle 
and adipose tissue (Lee et al., 2008, Gottfried et al., 2008). In clinical practice, the most 
widely used source of MSCs is bone marrow. The advantages of using bone marrow are the 
technique to collect them from the iliac crest is simple and is associated with the least 
morbidity. However, the problem of low MSC concentration upon harvest (1 in 10,000 cells) 
have led to an interest in adipose derived stem cells as they have been shown to have a 
higher prevalence (1 in 4,000 cells). The multipotentiality of adipose-derived stem cells 
(ADSCs) has been demonstrated in vivo and they have been shown to differentiate to bone 
cells in reaction to BMP signaling (Zuk et al., 2001, Zuk et al., 2010, Zuk et al., 2011). Hsu et 
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al. reported that stem cells from human adipose cell transfected with AdBMP-2 can work as 
cellular delivery vehicles in an athymic rat posterolateral spine fusion model (Hsu et al., 
2008). Miyazaki et al. have compared the osteogenic and osteoinductive ability between 
human bone marrow stem cells and human adipose derived stem cells for adenovirus 
mediated ex vivo gene therapy in an athymic rat spinal fusion model and demonstrated that 
both cells have similar ability for inducing new bone and spinal fusion (Miyazaki et al., 
2008) 
6. Spinal fusion by ex vivo gene therapy 
6.1 BMP-2 ex vivo gene therapy 
Riew et al attempted to prolong the bone-inducing effect of BMP-2 using an adenoviral 
vector carrying the human BMP-2 gene to transduce marrow-derived mesenchymal stem 
cells in New Zealand White rabbits. In their model, they isolated and expanded bone 
marrow mesenchymal cells from the resected ribs. Immunocytochemistry was used to show 
that approximately 80% of mesenchymal cells could be modified genetically to overexpress 
BMP-2 protein by treatment with an adenoviral vector encoding human BMP-2 (AdBMP-2). 
A similar efficiency of gen e transfer was shown with the control vector encoding a marker 
gene β-galactosidase (Adβ-gal). Four weeks after rib harvest, the rabbits underwent spinal 
fusion at L5-6. Genetically modified mesenchymal stem cells loaded onto collagen sponges 
were placed between the transverse processes of L5 and L6 with AdBMP-2 transduced 
mesenchymal stem cells placed on the left side and the Adβ-gal cells on the right. After the 
second postoperative week, all rabbits were examined weekly using a radiograph. Of the 
five study rabbits, one showed radiographic evidence of new bone formation on the side 
implanted with AdBMP-2 at 5 weeks after surgery. No new bone was noted on the control 
Adβ-gal side. No new bone formation was observed on either side in the other four study 
rabbits. Rabbits were sacrificed 7 weeks after the operation, and histologic examination of 
the rabbit with new bone revealed mature bone with a trabecular structure. The authors 
concluded that it was possible to transduce mesenchymal stem cells with human BMP-2 
gene so that the transformed cells could produce BMP-2 in vivo that would exert an 
osteoinductive effect (Riew et al., 1998). Riew et al also reported using ex vivo AdBMP-2 
transduction to perform anterior spinal fusion on pigs. Bone marrow cells were harvested 
from a resected rib and were expanded. Cells were then incubated overnight with AdBMP-
2. Anterior arthrodesis was performed by a thoracoscopic technique and the researchers 
reported a 100% fusion rate by histologic and radiologic evaluation for six of six disc spaces 
treated with AdBMP-2, whereas none of the controls fused (Riew et al., 2003). 
Wang et al. compared single-level posterolateral spine fusion rates between rhBMP-2 with 
various carriers, bone marrow cells transduced for 48 hours with AdBMP-2 and iliac crest 
bone graft (ICBG) in rats. They reported higher fusion rates with ex vivo BMP-2 transduction 
as compared with autogenous ICBG. All of the animals treated with AdBMP-2 and rhBMP-2 
achieved solid fusion masses at four weeks, whereas none of the control groups fused. 
Qualitatively, the ex vivo AdBMP-2-treated rats produced abundant trabecular fusion 
masses, whereas the rhBMP-2-treated rats exhibited thinner, lacelike trabecular fusion 
masses. The researchers concluded that ex vivo AdBMP-2 transduction produced solid 
posterolateral spinal fusion in rats and was superior to ICBG alone (Wang et al., 2003). The 
same group also reported that human bone marrow cells can be infected by AdBMP-2 and 
produce sufficient bone in vivo to fuse the lumbar spine in athymic rats (Peterson et al. 2005). 
Miyazaki et al. have compared lentiviral and adenoviral gene therapy. They had implanted 
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a collagen sponge containing rat bone marrow cells transfected with either Lenti-BMP-2 or 
Adeno-BMP-2 and achieved solid fusion masses at eight weeks, whereas the new bone 
volume and levels fused are greater in the Lenti-BMP-2 treated group. They concluded that 
lentiviral gene therapy with BMP-2 shows great potential for application in various 
pathologies of the spine despite the fact that the safety of using lentiviral vectors and the 
side effects of prolonged BMP-2 production are required to be elucidated before the 
application of this technology in humans (Miyazaki et al., 2008). 
6.2 BMP-7 ex vivo gene therapy 
Hidaka et al. recently reported successful posterolateral spinal fusion in immune-
competent rats in ex vivo study using rat bone marrow cells that were expanded for four 
weeks, then treated with AdBMP-7 or Adβ-gal for two hours. Three million cells were 
implanted with allograft bone at the L4-5 level using a paraspinal muscle-splitting 
approach. A β-galastosidase assay was performed in homogenetes of fusion masses 
harvested three, seven, and 14 days after surgery to evaluate the extent and duration of 
adenovirus mediated gene transfer in this model. The gene expression was maximal on 
day three, waning to background levels by 14 days. Additionally, with AdBMP-7 
treatment, radiographic fusion rates were 70% and mechanical fusion rates were 80% 
versus 0% by either parameter in control groups at eight weeks after the index procedure. 
Fusion masses of AdBMP-7 treated spines had the microscopic appearance of normal 
trabecular bone and showed a 23-fold higher uptake of fluorochrome indicating increased 
bone formation. (Hidaka et al., 2003).  
6.3 BMP-9 ex vivo gene therapy 
Dumont et al. reported that human bone marrow mesenchymal stem cells were transduced 
with AdBMP-9 or Adβ-gal for 12hours and then, the cells (1 million cells/ml) were injected 
into the lumbar region with the use of fluoroscopic guidance in an athymic rat model. At 
eight weeks, the sites treated with the cells transduced AdBMP-9 showed copious bone 
formation, whereas the control injections showed no osteogenic activity. They did not 
mention about the fusion rate or bone volume of the newly induced bone (Dumont et al., 
2002). 
6.4 Combination of different BMPs 
Although a variety of BMPs still are being investigated for their therapeutic potential, a 
combination of different BMPs and other growth factors may prove to be the most effective 
initiators of bone formation. The use of BMP2/7 and BMP4/7 heterodimers has 
demonstrated increased bone induction and compared with that of their homodimer 
counterparts (Israel et al., 1996). Zhu et al. reported that supernatants from the culture 
media of a producer cell (A549) co-transfected by AdBMP-2 and AdBMP-7 induced much 
higher osteocalcin expression and alkaline phosphatase activity in both C2C12 and MC3T3-
E-1 cells than the supernatants from the cells transfected either AdBMP-2 or AdBMP-7 alone 
even though the concentration of the produced BMPs are much lower in the co-transfected 
group. They further demonstrated that co administration of AdBMP-2 and AdBMP-7 
resulted in a significantly greater number of mechanically stable fusions ans also 2-fold 
higher mineralization rate and bone volume in the fusion mass versus single BMP gene 
transfer (co-administrated group; 73% fusion, AdBMP-2 group; 8% fusion and AdBMP-7 
group 16% fusion (Zhu et al., 2004). 
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6.5 LIM 
Although the exact mechanism of LMP-1 remains unclear, solid spinal fusions have been 
achieved in rat and rabbit models using ex vivo LMP-1-transduced bone marrow cells and 
buffy-coat blood cells.  
Boden et al investigated the feasibility of achieving lumbar spine fusion by liposomal-
mediated transfer of a different osteoinductive protein gene, the LIM mineralization protein-
1 (LMP-1) gene. LMP-1 is an intracellular protein that plays a key role in the BMP-6 
stimulation of osteoblasts. Because LMP-1 is an intracellular signaling molecule, the 
technique of gene therapy is best suited to deliver the LMP-1 cDNA within the cell. Marrow 
fibroblasts were isolated from the hind limbs of rats and transfected with a plasmid 
containing LMP-1 in the forward orientation (study group) or the reverse orientation 
(control group) using lipofection. Once the cells were transfected, they were soaked in a 
devitalized bone matrix carrier. 14 athymic rats were used. Implants were composed of a 
devitalized bone matrix carrier loaded with bone marrow cells transfected with either the 
LMP-1 gene (active) or the reverse LMP-1 (control). In the pilot phase, two rats received 
subcutaneous implants on the right (active) and left (control) sides of the chest. The same 
rats received implants to the lumbar (active) and received implants to the posterior thoracic 
(control) spine. In the experimental phase, 12 rats received active and control implants in the 
thoracic (T11-12) and lumbar (L5-6) spine. Rats that received bone marrow cells transfected 
with the active gene in the thoracic region and vice versa. Four weeks postoperation, all rats 
were sacrificed. The samples of the rats that received subcutaneous implants underwent 
high-definition radiographs and undecalcified histology. All thoracic and lumbar spines in 
the experimental group underwent assessment of fusion by manual palpation, radiography, 
and undecalcified histology. Examination of subcutaneous implants from the two pilot rats 
revealed complete bone formation with marrow and osteoblast-lined trabeculae on the 
active side (carrier plus marrow cells with active LMP-1 cDNA) with no bone formation on 
the control side (carrier plus marrow cells with reverse LMP-1 cDNA). The two lumbar 
spines of the pilot rats that were implanted with the active LMP-1 cDNA were completely 
fused, whereas the two thoracic control fusion sites that had been implanted with reverse 
LMP-1 cDNA failed to show new bone formation. In the experimental group, three of the 12 
rats died of perioperative anesthetic complications. In the remaining nine rats, complete 
arthrodesis was shown manually, radiographically, and histologically in nine of nine (100%) 
sites receiving bone marrow cells transfected with inactive LMP-1 cDNA were fused. The 
authors concluded that the local delivery of LMP-1 cDNA to bone marrow cells was feasible 
and efficacious for enhancing spine arthrodesis. 
 Boden et al. reported solid posterior fusion in an athymic rat model using bone marrow 
cells transduced for two hours with AdLMP-1 in a demineralized bone matrix carrier 
(Boden et al., 1998). Viggeswarapu et al. showed bone marrow or buffy-coat cells 
transduced with AdLMP-1 for 10 minutes combined with demineralized bone matrix or 
collagen-ceramic-composite sponges induced posterolateral lumbar fusion in rabbits 
(Viggeswarapu et al., 2001). 
6.6 Nell-1 
Lu et al reported the osteoinductive properties of Nell-1 in rat spinal fusion model. 
Demineralized bone matrix (DBM) carriers containing either adenovirus coding for Nell-1 
(AdNell-1) or Lac Z (AdLacZ) were implanted at the intertransverse process of L4-5 in 
athymic rats. After six weeks, direct application of adenoviral Nell-1 in a DBM carrier 
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achieved significantly higher rates of spinal fusion over Lac Z controls: 60% Nell-1 versus 
20% Lac Z by manual palpation and 70% Nell-1 versus 20% Lac Z by micoroCT and 
histology. Histological assessment of bone quality and maturity revealed more mature, 
higher quality bone in all the Nell-1 treated specimens relative to Lac Z at six weeks. They 
concluded that Nell-1, which is regulated by the master bone regulatory gene Runx2, may 
exert its effects more specifically in osteoblastic cells than BMPs which affects multiple cell 
types. 
7. Conclusion and future direction 
Spinal fusion will continue to be an important part of the surgical treatment of spinal 
pathology for the foreseeable future. Promising research in progress involves the 
understanding of the biology of bone formation (White et al., 2004) and the use of gene  
 
Authors Vector Gene cell animal 
Fusion 
rate 
F/U 
weeks 
carrier 
Riew et al adenovirus
BMP-
2 
Rat BMC rabbits 20% 7 collagen 
Boden et al plasmid LIM-1 Ratfibloblast
Athymic 
rats 
100% 4 DBM 
Peterson et al adenovirus
BMP-
2 
Human BMC
Athymic 
rats 
100% 12 CS 
Wang et al adenovirus
BMP-
2 
Rat BMC rats 100% 8 DBM 
Hsu et al adenovirus
BMP-
2 
Human 
ADSC 
Athymic 
rats 
100% 12 CS 
Miyazaki et al lentivirus
BMP-
2 
Rat BMC rats 100% 8 CS 
Viggeswarapu et 
al 
adenovirus LIM-1
BCC 
rabbits 100% 
5 DBM 
PBC 4 CCC 
Hidaka et al adenovirus
BMP-
7 
Rat BMC rats 70% 8 allograft 
Dumont et al adenovirus
BMP-
9 
Human BMC
Athymic 
rats 
N/A 8 none 
Riew et al adenovirus
BMP-
2 
Pig BMC pigs 100% 6 none 
Miyazaki et al 
adenovirus BMP-
2 
Rat BMC rats 100% 8 CS 
lentivirus
Miyazaki et al adenovirus
BMP-
2 
Human 
ADSC 
Athymic 
rats 
100% 8 CS 
Human BMC
Lu et al adenovirus Nell-1 none 
Athymic 
rats 
70% 6 DBM 
BMC: bone marrow cell, ADSC: adipose derived stem cell, CCC: collagen-ceramic-composite, CS: 
collagen sponge, Buffy-coat cell: BCC, Peripheral blood cell: PBC 
Table 1. Animal studies on ex vivo gene therapy for spinal fusion. 
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therapy or tissue engineering in facilitating the natural processes of a spinal fusion. A viral 
vector can be used to transfer a gene into human cells to produce various recombinant 
growth factors that may modify the fusion cascade both qualitatively and quantitatively. 
Viral vectors, particularly the adenovirus, may serve as transports for the material encoding 
osteogenic factors. However, significant advances need to be made in vector design for low 
immunogenetic potential, controlled gene expression techniques like tetracycline-regulated 
system, the way of preventing insertional mutagenesis, and tissue targeting before human 
clinical trials can be safely and successfully conducted. 
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